Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 13 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8334373

    Nuclease resistant double-stranded ribonucleic acid

    Alnylam Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  2. US 8324368

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted

  3. US 8324366

    Compositions and methods for delivering RNAI using lipoproteins

    Alnylam Pharmaceuticals, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted

  4. US 8318693

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 27, 2012 · Expires Nov 22, 2032

    granted

  5. US 8293719

    iRNA agents targeting VEGF

    Alnylam Pharmaceuticals, Inc. · Granted Oct 23, 2012 · Expires Oct 18, 2032

    granted

  6. US 8288525

    Compositions and methods for inhibiting expression of CD45 gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 16, 2012 · Expires Oct 11, 2032

    granted

  7. US 8273868

    Compositions and methods for inhibiting viral replication

    Alnylam Pharmaceuticals, Inc. · Granted Sep 25, 2012 · Expires Sep 20, 2032

    granted

  8. US 8273870

    Compositions and methods for inhibiting expression of a mutant gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 25, 2012 · Expires Sep 20, 2032

    granted

  9. US 8273869

    Lipid formulated dsRNA targeting the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 25, 2012 · Expires Sep 20, 2032

    granted

  10. US 8268799

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 18, 2012 · Expires Sep 13, 2032

    granted

  11. US 8263572

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted

  12. US 8227188

    Enhancement of influenza gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Jul 24, 2012 · Expires Jul 19, 2032

    granted

  13. US 8222222

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 17, 2012 · Expires Jul 12, 2032

    granted

  14. US 8202980

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 19, 2012 · Expires Jun 14, 2032

    granted

  15. US 8188061

    RNAi modulation of APOB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 29, 2012 · Expires May 24, 2032

    granted

  16. US 8183362

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted May 22, 2012 · Expires May 17, 2032

    granted

  17. US 8168776

    Method for making a 21 nucleotide double stranded RNA chemically linked at one end

    Alnylam Pharmaceuticals, Inc. · Granted May 1, 2012 · Expires Apr 26, 2032

    granted

  18. US 8168775

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted May 1, 2012 · Expires Apr 26, 2032

    granted

  19. US 8163711

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 24, 2012 · Expires Apr 19, 2032

    granted

  20. US 8158601

    Lipid formulation

    Alnylam Pharmaceuticals, Inc. · Granted Apr 17, 2012 · Expires Apr 12, 2032

    granted

  21. US 8158773

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 17, 2012 · Expires Apr 12, 2032

    granted

  22. US 8148344

    Compositions and methods for mediating RNAi in vivo

    Alnylam Pharmaceuticals, Inc. · Granted Apr 3, 2012 · Expires Mar 29, 2032

    granted

  23. US 8143390

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Pharmaceuticals, Inc. · Granted Mar 27, 2012 · Expires Mar 22, 2032

    granted

  24. US 8119608

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 21, 2012 · Expires Feb 16, 2032

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.